High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
Authors
Keywords
-
Journal
RHEUMATOLOGY INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-18
DOI
10.1007/s00296-020-04699-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
- (2020) Philippe Guilpain et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
- (2020) Sara Monti et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’
- (2020) Kristin M D’Silva et al. ANNALS OF THE RHEUMATIC DISEASES
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
- (2020) Ennio Giulio Favalli et al. JOURNAL OF RHEUMATOLOGY
- Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
- (2020) Rebecca Haberman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab
- (2020) Benedict Fallet et al. Arthritis & Rheumatology
- Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
- (2020) Carlos Sanchez-Piedra et al. ANNALS OF THE RHEUMATIC DISEASES
- Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
- (2020) Jérôme Avouac et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
- (2020) Laura Nuño et al. ANNALS OF THE RHEUMATIC DISEASES
- Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia
- (2020) Samy Hakroush et al. ANNALS OF THE RHEUMATIC DISEASES
- Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
- (2020) Maurizio Benucci et al. ANNALS OF THE RHEUMATIC DISEASES
- Mild COVID-19 in ANCA-associated vasculitis treated with rituximab
- (2020) Silvia Suárez-Díaz et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2
- (2020) Zsófia Iglói et al. JOURNAL OF CLINICAL VIROLOGY
- Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
- (2020) Xabier Michelena et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
- (2019) Kathrine Lederballe Grøn et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare
- (2015) Huifeng Yun et al. Arthritis & Rheumatology
- CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?
- (2014) Panagiotis Pateinakis et al. Biomed Research International
- B cells participate in tolerance and autoimmunity through cytokine production
- (2013) Van Phi Luu et al. AUTOIMMUNITY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now